[{"id":"ecd3b97e-f85f-4235-ac7a-4003f3339215","acronym":"NEOpredict-EGF","url":"https://clinicaltrials.gov/study/NCT06784791","created_at":"2025-02-25T14:44:13.644Z","updated_at":"2025-02-25T14:44:13.644Z","phase":"Phase 2","brief_title":"Preoperative Amivantamab or Amivantamab and Carboplatin/pemetrexed Treatment in Patients with Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)","source_id_and_acronym":"NCT06784791 - NEOpredict-EGF","lead_sponsor":"University Hospital, Essen","biomarkers":" EGFR • CD8 • CD163 • CD4 • NCAM1 • CD68","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR • CD8 • CD163 • CD4 • NCAM1 • CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/06/2024","start_date":" 11/06/2024","primary_txt":" Primary completion: 07/31/2027","primary_completion_date":" 07/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-14"},{"id":"34985820-886b-4e61-90e7-8b16e17a8048","acronym":"MEMENTO","url":"https://clinicaltrials.gov/study/NCT06687876","created_at":"2025-02-25T19:17:34.383Z","updated_at":"2025-02-25T19:17:34.383Z","phase":"Phase 2","brief_title":"Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy","source_id_and_acronym":"NCT06687876 - MEMENTO","lead_sponsor":"Amsterdam UMC, location VUmc","biomarkers":" CD163","pipe":"","alterations":" ","tags":["CD163"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • metformin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 14","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2024-11-18"},{"id":"245ed9e1-ca34-4788-8cc3-6546ba073450","acronym":"","url":"https://clinicaltrials.gov/study/NCT06573398","created_at":"2025-02-27T08:15:39.768Z","updated_at":"2025-02-27T08:15:39.768Z","phase":"Phase 2","brief_title":"Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC","source_id_and_acronym":"NCT06573398","lead_sponsor":"Ruijin Hospital","biomarkers":" CD8 • CD163 • CD4 • CD68 • CD86","pipe":"","alterations":" ","tags":["CD8 • CD163 • CD4 • CD68 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • Zadaxin (thymalfasin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2024","start_date":" 09/01/2024","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-08-27"},{"id":"c3c05277-42e5-4669-bea5-688ad1660501","acronym":"","url":"https://clinicaltrials.gov/study/NCT06001658","created_at":"2023-08-21T14:08:46.484Z","updated_at":"2025-02-25T16:19:01.820Z","phase":"Phase 2","brief_title":"Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers","source_id_and_acronym":"NCT06001658","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD8 • CD163 • CD68","pipe":" | ","alterations":" ARG1 overexpression • CD163 expression","tags":["CD8 • CD163 • CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARG1 overexpression • CD163 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • gemcitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 07/08/2024","start_date":" 07/08/2024","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-07-25"},{"id":"6abdabcb-20ec-463a-9da6-da3f3fef4258","acronym":"","url":"https://clinicaltrials.gov/study/NCT03502330","created_at":"2021-01-18T17:14:06.052Z","updated_at":"2025-02-25T14:26:50.517Z","phase":"Phase 1","brief_title":"APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma","source_id_and_acronym":"NCT03502330","lead_sponsor":"Yale University","biomarkers":" PD-L1 • BRAF • CD8 • IFNG • CD163 • IL10 • CD40LG","pipe":" | ","alterations":" EGFR mutation • EGFR T790M • ALK rearrangement","tags":["PD-L1 • BRAF • CD8 • IFNG • CD163 • IL10 • CD40LG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cabiralizumab (BMS-986227) • sotigalimab (PYX-107)"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 06/09/2018","start_date":" 06/09/2018","primary_txt":" Primary completion: 01/05/2022","primary_completion_date":" 01/05/2022","study_txt":" Completion: 05/15/2024","study_completion_date":" 05/15/2024","last_update_posted":"2024-07-03"},{"id":"114d9c89-e0e5-473e-a324-f2022f9b4244","acronym":"","url":"https://clinicaltrials.gov/study/NCT04465643","created_at":"2021-01-18T21:27:49.677Z","updated_at":"2025-02-25T14:29:26.270Z","phase":"Phase 1","brief_title":"Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor","source_id_and_acronym":"NCT04465643","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" PD-L1 • CD20 • CD8 • PD-1 • LAG3 • CD276 • CTLA4 • PD-L2 • VTCN1 • HAVCR2 • IL2RA • CD163 • TIGIT • PTPRC • NCAM1 • ICOS • CD14 • CD68 • GZMB • ITGAM • BTLA • FOXP3 • MRC1 • ISG20","pipe":"","alterations":" ","tags":["PD-L1 • CD20 • CD8 • PD-1 • LAG3 • CD276 • CTLA4 • PD-L2 • VTCN1 • HAVCR2 • IL2RA • CD163 • TIGIT • PTPRC • NCAM1 • ICOS • CD14 • CD68 • GZMB • ITGAM • BTLA • FOXP3 • MRC1 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 06/08/2021","start_date":" 06/08/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-06-21"},{"id":"23dbdc8e-972e-4762-87c9-f40d67d274d3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05080946","created_at":"2021-10-18T12:53:00.791Z","updated_at":"2024-07-02T16:34:26.049Z","phase":"Phase 1","brief_title":"Using Aspirin to Improve Immunological Features of Ovarian Tumors","source_id_and_acronym":"NCT05080946","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" CD163 • FOXP3","pipe":"","alterations":" ","tags":["CD163 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/02/2021","start_date":" 11/02/2021","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-06-14"},{"id":"ce6acbdf-d0c9-46e4-a247-444e713619ba","acronym":"","url":"https://clinicaltrials.gov/study/NCT06413095","created_at":"2024-05-18T04:21:47.057Z","updated_at":"2025-02-25T16:02:48.188Z","phase":"Phase 1","brief_title":"PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS","source_id_and_acronym":"NCT06413095","lead_sponsor":"Presage Biosciences","biomarkers":" CD8 • IFNG • CD163 • GZMB","pipe":"","alterations":" ","tags":["CD8 • IFNG • CD163 • GZMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • MK-0482 • MK-4830"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 06/22/2023","primary_completion_date":" 06/22/2023","study_txt":" Completion: 06/22/2023","study_completion_date":" 06/22/2023","last_update_posted":"2024-05-14"},{"id":"b8813467-068d-4010-8e2e-a3efe97a80e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02379377","created_at":"2021-01-18T11:20:05.224Z","updated_at":"2024-07-02T16:35:05.006Z","phase":"Phase 1","brief_title":"18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant","source_id_and_acronym":"NCT02379377","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD163 • CASP3 • CD86","pipe":"","alterations":" ","tags":["CD163 • CASP3 • CD86"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 02/15/2022","start_date":" 02/15/2022","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2024-05-08"},{"id":"1d4dd198-7dd9-44b5-bf2f-70642e346bc2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06400160","created_at":"2024-05-11T04:34:11.020Z","updated_at":"2024-07-02T16:35:05.740Z","phase":"Phase 1/2","brief_title":"Clinical Trial of TB511 in Advanced Solid Tumors","source_id_and_acronym":"NCT06400160","lead_sponsor":"Twinpig Biolab, Inc.","biomarkers":" CD8 • IFNG • TNFA • IL2RA • CD163 • PTPRC • IL2 • NCAM1 • IL10 • GZMB • ITGB2","pipe":" | ","alterations":" IL2-L","tags":["CD8 • IFNG • TNFA • IL2RA • CD163 • PTPRC • IL2 • NCAM1 • IL10 • GZMB • ITGB2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL2-L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 10/01/2024","start_date":" 10/01/2024","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2024-05-06"},{"id":"39769fed-659c-4bfe-8a22-cc44cf784049","acronym":"","url":"https://clinicaltrials.gov/study/NCT04541108","created_at":"2021-01-18T21:43:38.590Z","updated_at":"2024-07-02T16:35:08.887Z","phase":"Phase 1","brief_title":"Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies","source_id_and_acronym":"NCT04541108","lead_sponsor":"Presage Biosciences","biomarkers":" CD8 • TNFA • CD163 • CD4 • NCAM1 • CASP3 • CD68 • GZMB • CD86","pipe":"","alterations":" ","tags":["CD8 • TNFA • CD163 • CD4 • NCAM1 • CASP3 • CD68 • GZMB • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • paclitaxel • 5-fluorouracil • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • BMS-986299 • MK-0482 • MK-4830 • dazostinag (TAK-676) • sabestomig (AZD7789)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 07/26/2021","start_date":" 07/26/2021","primary_txt":" Primary completion: 12/01/2031","primary_completion_date":" 12/01/2031","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-04-18"},{"id":"83026695-d43a-4653-bca6-29f8b4ee5021","acronym":"REVOLUMAB","url":"https://clinicaltrials.gov/study/NCT03925246","created_at":"2021-01-18T19:18:33.109Z","updated_at":"2025-02-25T14:28:20.050Z","phase":"Phase 2","brief_title":"Efficacy of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas","source_id_and_acronym":"NCT03925246 - REVOLUMAB","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" PD-L1 • TMB • IDH1 • IDH2 • MGMT • CD8 • PD-1 • ATRX • CD163 • CD4 • CD68 • FOXP3 • GFAP • OLIG2","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation • IDH1 R132","tags":["PD-L1 • TMB • IDH1 • IDH2 • MGMT • CD8 • PD-1 • ATRX • CD163 • CD4 • CD68 • FOXP3 • GFAP • OLIG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • temozolomide"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 07/30/2019","start_date":" 07/30/2019","primary_txt":" Primary completion: 12/02/2020","primary_completion_date":" 12/02/2020","study_txt":" Completion: 08/18/2021","study_completion_date":" 08/18/2021","last_update_posted":"2024-04-02"},{"id":"e7a174b3-87f7-443a-b744-e941f8c6673e","acronym":"KEYNOTE-E20","url":"https://clinicaltrials.gov/study/NCT05311618","created_at":"2022-04-05T13:52:37.035Z","updated_at":"2025-02-25T16:17:32.726Z","phase":"Phase 1","brief_title":"Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05311618 - KEYNOTE-E20","lead_sponsor":"NGM Biopharmaceuticals, Inc","biomarkers":" CD8 • CD163 • MMP9","pipe":"","alterations":" ","tags":["CD8 • CD163 • MMP9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • NGM438"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 71","initiation":"Initiation: 05/11/2022","start_date":" 05/11/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-04-01"},{"id":"3a511d5d-3245-4fbd-a2c8-a89db4e723ed","acronym":"CIFRA","url":"https://clinicaltrials.gov/study/NCT03874026","created_at":"2021-01-18T19:06:05.689Z","updated_at":"2024-07-02T16:35:12.803Z","phase":"Phase 2","brief_title":"Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients","source_id_and_acronym":"NCT03874026 - CIFRA","lead_sponsor":"National Cancer Institute, Naples","biomarkers":" KRAS • BRAF • IFNG • TNFA • CD163 • GZMB • TGFB1 • FOXP3 • CD86","pipe":" | ","alterations":" KRAS wild-type • BRAF wild-type • NRAS wild-type • CD163 expression","tags":["KRAS • BRAF • IFNG • TNFA • CD163 • GZMB • TGFB1 • FOXP3 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • BRAF wild-type • NRAS wild-type • CD163 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • irinotecan"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 09/05/2019","start_date":" 09/05/2019","primary_txt":" Primary completion: 05/19/2023","primary_completion_date":" 05/19/2023","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2024-03-26"},{"id":"e8a0c5a3-854f-4878-82dd-a53e0b5e2e5b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05698199","created_at":"2023-11-22T19:16:45.757Z","updated_at":"2024-07-02T16:35:12.688Z","phase":"Phase 1","brief_title":"Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)","source_id_and_acronym":"NCT05698199","lead_sponsor":"Immunomic Therapeutics, Inc.","biomarkers":" CD8 • CD163 • FOXP3","pipe":"","alterations":" ","tags":["CD8 • CD163 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ITI-1001"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 08/21/2023","start_date":" 08/21/2023","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-03-26"},{"id":"495ae210-14e3-4dc2-9bda-5e696bcb61a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT06056804","created_at":"2023-11-19T01:16:40.961Z","updated_at":"2024-07-02T16:35:28.894Z","phase":"Phase 2","brief_title":"Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer","source_id_and_acronym":"NCT06056804","lead_sponsor":"Beijing Friendship Hospital","biomarkers":" CD8 • CD163 • CD4 • CD68 • CD86","pipe":" | ","alterations":" CD163 expression • CD4 expression","tags":["CD8 • CD163 • CD4 • CD68 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD163 expression • CD4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • capecitabine • Zadaxin (thymalfasin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2023-11-17"},{"id":"67716777-5690-49d3-993c-981578cca089","acronym":"NUTOBREST","url":"https://clinicaltrials.gov/study/NCT06046755","created_at":"2023-09-21T15:11:09.919Z","updated_at":"2024-07-02T16:35:36.338Z","phase":"","brief_title":"Nutritional Intervention-induced Weight Loss During the Oncological Treatment of Obesity-related Breast Cancer","source_id_and_acronym":"NCT06046755 - NUTOBREST","lead_sponsor":"Hospital Clinico Universitario de Santiago","biomarkers":" TNFRSF8 • TNFA • CD163 • IL6R • IL22 • TSLP • IFNL1 • IFNL2 • MMP3","pipe":"","alterations":" ","tags":["TNFRSF8 • TNFA • CD163 • IL6R • IL22 • TSLP • IFNL1 • IFNL2 • MMP3"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 10/15/2023","start_date":" 10/15/2023","primary_txt":" Primary completion: 10/03/2024","primary_completion_date":" 10/03/2024","study_txt":" Completion: 12/21/2025","study_completion_date":" 12/21/2025","last_update_posted":"2023-09-21"},{"id":"83112f9b-4b22-4336-82d3-68d2e46ecb8f","acronym":"PRO-IMMUNO","url":"https://clinicaltrials.gov/study/NCT06016699","created_at":"2023-08-30T14:08:41.186Z","updated_at":"2024-07-02T16:35:38.551Z","phase":"","brief_title":"Immunological Function After Radiation With Either Proton or Photon Therapy","source_id_and_acronym":"NCT06016699 - PRO-IMMUNO","lead_sponsor":"University Medical Center Groningen","biomarkers":" CD20 • CD8 • PD-1 • CD163 • CD4 • CD68 • FOXP3","pipe":"","alterations":" ","tags":["CD20 • CD8 • PD-1 • CD163 • CD4 • CD68 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 09/23/2021","start_date":" 09/23/2021","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2023-08-30"},{"id":"fb8dc3ab-b4a9-4b4d-aae6-7233509f61b6","acronym":"Neo Combi","url":"https://clinicaltrials.gov/study/NCT01972347","created_at":"2021-03-01T20:52:35.949Z","updated_at":"2024-07-02T16:35:38.660Z","phase":"Phase 2","brief_title":"Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma","source_id_and_acronym":"NCT01972347 - Neo Combi","lead_sponsor":"Melanoma Institute Australia","biomarkers":" EGFR • CD20 • CD8 • PD-1 • CCND1 • MCL1 • IL6 • CTNNB1 • TNFA • CD163 • CD4 • IL10 • CD68 • IL18 • FOXP3 • CDKN1A","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["EGFR • CD20 • CD8 • PD-1 • CCND1 • MCL1 • IL6 • CTNNB1 • TNFA • CD163 • CD4 • IL10 • CD68 • IL18 • FOXP3 • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 05/04/2017","primary_completion_date":" 05/04/2017","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2023-08-30"},{"id":"e845dc0d-c6e6-45c0-b502-ea4306aa1e6f","acronym":"PRINCE","url":"https://clinicaltrials.gov/study/NCT04589013","created_at":"2021-01-18T21:53:20.046Z","updated_at":"2024-07-02T16:35:57.042Z","phase":"","brief_title":"Prediction of Response to Treatment With Immunotherapy + Chemotherapy in Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04589013 - PRINCE","lead_sponsor":"University Hospital, Lille","biomarkers":" PD-L1 • CD8 • PD-1 • CD163 • FOXP3","pipe":"","alterations":" ","tags":["PD-L1 • CD8 • PD-1 • CD163 • FOXP3"],"overall_status":"Recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 11/19/2020","start_date":" 11/19/2020","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 11/01/2023","study_completion_date":" 11/01/2023","last_update_posted":"2023-01-26"},{"id":"5363ddba-ce3b-4487-8a21-7cccbee4cdbe","acronym":"INTRANS","url":"https://clinicaltrials.gov/study/NCT03754140","created_at":"2021-06-15T21:52:36.260Z","updated_at":"2024-07-02T16:36:07.298Z","phase":"Phase 2","brief_title":"Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases","source_id_and_acronym":"NCT03754140 - INTRANS","lead_sponsor":"Melanoma Institute Australia","biomarkers":" CD20 • CD8 • CD163 • CD4 • NCAM1 • CD68 • CD31 • FOXP3 • PECAM1","pipe":"","alterations":" ","tags":["CD20 • CD8 • CD163 • CD4 • NCAM1 • CD68 • CD31 • FOXP3 • PECAM1"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/20/2020","start_date":" 05/20/2020","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2022-07-14"},{"id":"01bab055-3bba-471a-9ff9-022c1458fb21","acronym":"","url":"https://clinicaltrials.gov/study/NCT04891718","created_at":"2021-05-18T12:02:12.873Z","updated_at":"2025-02-25T14:59:52.160Z","phase":"Phase 1","brief_title":"CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia","source_id_and_acronym":"NCT04891718","lead_sponsor":"Presage Biosciences","biomarkers":" CD8 • CD163 • CD4 • NCAM1 • CASP3 • CD68 • GZMB • CD86","pipe":"","alterations":" ","tags":["CD8 • CD163 • CD4 • NCAM1 • CASP3 • CD68 • GZMB • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • TAK-186"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/15/2021","start_date":" 09/15/2021","primary_txt":" Primary completion: 06/05/2022","primary_completion_date":" 06/05/2022","study_txt":" Completion: 06/05/2022","study_completion_date":" 06/05/2022","last_update_posted":"2022-07-08"},{"id":"d7250f67-4645-4aee-9249-1bb54b6cd454","acronym":"TANOs","url":"https://clinicaltrials.gov/study/NCT04867421","created_at":"2021-04-30T11:55:07.437Z","updated_at":"2024-07-02T16:36:09.921Z","phase":"","brief_title":"Neutrophils in Bone Sarcomas","source_id_and_acronym":"NCT04867421 - TANOs","lead_sponsor":"Université de Reims Champagne-Ardenne","biomarkers":" PD-L1 • CD8 • CD163 • PTPRC • CCR5 • CD80 • CEACAM8","pipe":"","alterations":" ","tags":["PD-L1 • CD8 • CD163 • PTPRC • CCR5 • CD80 • CEACAM8"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 09/01/2020","start_date":" 09/01/2020","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2022-05-25"},{"id":"4e579bc4-0edb-4785-98c5-7919d0eac97b","acronym":"DOMEC","url":"https://clinicaltrials.gov/study/NCT03951415","created_at":"2021-04-01T23:53:05.952Z","updated_at":"2025-02-25T15:08:32.159Z","phase":"Phase 2","brief_title":"Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer","source_id_and_acronym":"NCT03951415 - DOMEC","lead_sponsor":"Leiden University Medical Center","biomarkers":" PD-1 • LAG3 • CTLA4 • CD163 • CD14 • CD68 • ITGAE • KLRB1 • KLRC1","pipe":"","alterations":" ","tags":["PD-1 • LAG3 • CTLA4 • CD163 • CD14 • CD68 • ITGAE • KLRB1 • KLRC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 07/08/2019","start_date":" 07/08/2019","primary_txt":" Primary completion: 08/01/2021","primary_completion_date":" 08/01/2021","study_txt":" Completion: 08/01/2021","study_completion_date":" 08/01/2021","last_update_posted":"2021-04-01"}]